Incumbent U.S. Representative Tom Malinowski (D-NJ-07) appears to have financially benefited from exceptional timing during the COVID-19 pandemic.
The Hill reported in 2021 that Malinowski previously faced two ethics complaints about his failure to report “trading roughly $1 million in stock in medical companies that were involved in responses to the COVID-19 pandemic.”
Read More